Page 1110 - Hematology_ Basic Principles and Practice ( PDFDrive )

980 Part VII Hematologic Malignancies

Malcovati L, Germing U, Kuendgen A, et al: Time-dependent prognostic 3. Hewlett J, Kopecky KJ, Head D, et al: A prospective evaluation of
scoring system for predicting survival and leukemic evolution in myelo- the roles of allogeneic marrow transplantation and low-dose monthly
dysplastic syndromes. J Clin Oncol 25:3503, 2007. maintenance chemotherapy in the treatment of adult acute myelogenous
Malcovati L, Porta MG, Pascutto C, et al: Prognostic factors and life expec- leukemia (AML): a Southwest Oncology Group study. Leukemia 9:562,
tancy in myelodysplastic syndromes classified according to WHO criteria: 1995.
a basis for clinical decision making. J Clin Oncol 23:7594, 2005. 4. Sierra J, Brunet S, Granena A, et al: Catalan Group for Bone Marrow
McClune BL, Weisdorf DJ, Pedersen TL, et al: Effect of age on outcome of Transplantation: feasibility and results of bone marrow transplantation
reduced-intensity hematopoietic cell transplantation for older patients after remission induction and intensification chemotherapy in de novo
with acute myeloid leukemia in first complete remission or with myelo- acute myeloid leukemia. J Clin Oncol 14:1353, 1996.
dysplastic syndrome. J Clin Oncol 28:1878, 2010. 5. Keating S, de Witte T, Suciu S, et al: European Organization for Research
Rockova V, Abbas S, Wouters BJ, et al: Risk stratification of intermediate- and Treatment of Cancer, Gruppo Italiano Malattie Ematologiche
risk acute myeloid leukemia: integrative analysis of a multitude of gene Maligne dell’Adulto: the influence of HLA-matched sibling donor
mutation and gene expression markers. Blood 118:1069, 2011. availability on treatment outcome for patients with AML: an analysis of
Schanz J, Steidl C, Fonatsch C, et al: Coalesced multicentric analysis of 2,351 the AML 8A study of the EORTC Leukaemia Cooperative Group and
patients with myelodysplastic syndromes indicates an underestimation of GIMEMA. Br J Haematol 102:1344, 1998.
poor-risk cytogenetics of myelodysplastic syndromes in the international 6. Slovak ML, Kopecky KJ, Cassileth PA, et al: Karyotypic analysis predicts
prognostic scoring system. J Clin Oncol 29:1963, 2011. outcome of preremission and postremission therapy in adult acute
Schlenk RF, Dohner K, Krauter J, et al: Mutations and treatment outcome in myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative
cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909, Oncology Group Study. Blood 96:4075, 2000.
2008. 7. Suciu S, Mandelli F, de Witte T, et al, EORTC and GIMEMA Leukemia
Walter RB, Pagel JM, Gooley TA, et al: Comparison of matched unrelated Groups: Allogeneic compared with autologous stem cell transplantation
and matched related donor myeloablative hematopoietic cell transplanta- in the treatment of patients younger than 46 years with acute myeloid
tion for adults with acute myeloid leukemia in first remission. Leukemia leukemia (AML) in first complete remission (CR1): an intention-to-treat
24:1276, 2010. analysis of the EORTC/GIMEMAAML-10 trial. Blood 102:1232, 2003.
8. Jourdan E, Boiron JM, Dastugue N, et al: Early allogeneic stem-cell
transplantation for young adults with acute myeloblastic leukemia in first
SOURCES CITED IN FIG. 61.1 complete remission: an intent-to-treat long-term analysis of the BGMT
experience. J Clin Oncol 23:7676, 2005.
1. Schiller GJ, Nimer SD, Territo MC, et al: Bone marrow transplantation 9. Burnett AK, Wheatley K, Goldstone AH, et al: Longterm results of the
versus high-dose cytarabine based consolidation chemotherapy for acute MRC AML10 trial. Clin Adv Hematol Oncol 4:445, 2006.
myelogenous leukemia in first remission. J Clin Oncol 10:41, 1992. 10. Cornelissen JJ, van Putten WL, Verdonck LF, et al: Results of a HOVON/
2. Archimbaud E, Thomas X, Michallet M, et al: Prospective genetically SAKK donor versus no-donor analysis of myeloablative HLA-identical
randomized comparison between intensive postinduction chemotherapy sibling stem cell transplantation in first remission acute myeloid leukemia
and bone marrow transplantation in adults with newly diagnosed acute in young and middle-aged adults: benefits for whom? Blood 109:3658,
myeloid leukemia. J Clin Oncol 12:262, 1994. 2007.